Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI Keeps Buy on WUXI BIO, LIfts TP to HKD39
Recommend 1 Positive 4 Negative 0 |
||||
|
||||
|
According to a CMBI research report, WUXI BIO (02269.HK)'s 2025 revenue and adjusted net profit grew by 16.7% and 17.9% YoY, beating the broker's forecasts by 1.2% and 9.6%, respectively. According to the preliminary guidance from management, the company's revenue is expected to grow by 13-17% this year, and the growth rate could be even higher if the potential impact of foreign exchange fluctuations is excluded. Given the improved visibility of its growth, CMBI has lifted its target price for WUXI BIO from HKD35.6 to HKD39 and kept the Buy rating unchanged. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
